Traders should monitor ramp-up timing toward full capacity and future EMA approval prospects, which could expand market access. The revenue contribution is modest but strategically significant for Kamada’s plasma supply chain and third-party sales growth.
Price Chart
Executive Summary
Kamada Ltd. announced FDA approval for its San Antonio plasma collection center, enabling commercial sales of normal source plasma. The facility has an annual capacity of 50,000 liters and is expected to generate $8 million to $10 million in annual revenue at full capacity, supporting growth in specialty plasma collection and third-party plasma sales.
Key Financial Metrics
Key Facts
- FDA approved Kamada's San Antonio plasma collection center following a February 2026 inspection.
- Facility has 50 donor beds and can collect up to 50,000 liters of plasma annually.
- Expected annual revenue contribution of $8M–$10M from normal source plasma sales at full capacity.
- San Antonio center is one of three FDA-approved U.S. plasma centers, alongside Houston and Beaumont.
- Kamada plans to seek EMA approval for the San Antonio site following FDA clearance.
Financial Impact
Adds $8M–$10M in annual revenue at full capacity from plasma sales
Risk Factors
- Revenue projections are forward-looking and dependent on achieving full collection capacity.
- Geopolitical risks in the Middle East could disrupt operations in Israel, affecting overall business stability.
- Regulatory delays possible for EMA approval of the San Antonio center.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262840 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | EFFECT | $8.19 $8.77 | ▲ +7.08% | ▲ +4.52% | $8.20 (+0.12%) |
Sep 10, 2026 22d ago | 6-K | $7.99 $8.67 | ▲ +8.51% | ▲ +9.01% | $8.20 (+2.63%) |
Sep 3, 2026 29d ago | Press Release | $8.54 $8.31 | ▼ −2.69% | ▼ −1.48% | $8.20 (−3.98%) |
Sep 3, 2026 29d ago | 6-K | $8.54 $8.31 | ▼ −2.69% | ▼ −1.48% | $8.20 (−3.98%) |
Aug 17, 2026 6w ago | 6-K / PRESS-RELEASE | $7.76 $8.43 | ▲ +8.63% | ▲ +9.82% | $8.20 (+5.67%) |
Aug 12, 2026 7w ago | 6-K | $6.88 $7.89 | ▲ +14.68% | ▲ +15.12% | $8.20 (+19.19%) |
Aug 5, 2026 8w ago | 6-K | $7.14 $7.26 | ▲ +1.68% | ▲ +0.47% | $8.20 (+14.85%) |
Aug 5, 2026 8w ago | 6-K | $7.18 $6.88 | ▼ −4.18% | ▼ −4.53% | $8.20 (+14.21%) |
Jul 20, 2026 10w ago | 6-K | $7.09 $7.06 | ▼ −0.42% | ▲ +0.00% | $8.20 (+15.66%) |
Jul 13, 2026 11w ago | 6-K | $7.17 $7.05 | ▼ −1.67% | ▼ −0.89% | $8.20 (+14.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access